Timing and Predictors of Initiation on Antiretroviral Therapy Among Newly-Diagnosed HIV-Infected Persons in South Africa.


Journal

AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 17 7 2018
medline: 26 4 2019
entrez: 16 7 2018
Statut: ppublish

Résumé

Despite a decade of advancing HIV/AIDS treatment policy in South Africa, 20% of people living with HIV (PLHIV) eligible for antiretroviral treatment (ART) remain untreated. To inform universal test and treat (UTT) implementation in South Africa, this analysis describes the rate, timeliness and determinants of ART initiation among newly diagnosed PLHIV. This analysis used routine data from 35 purposively selected primary clinics in three high HIV-burden districts of South Africa from June 1, 2014 to March 31, 2015. Kaplan-Meier survival curves estimated the rate of ART initiation. We identified predictors of ART initiation rate and timely initiation (within 14 days of eligibility determination) using Cox proportional hazards and multivariable logistic regression models in Stata 14.1. Based on national guidelines, 6826 patients were eligible for ART initiation. Under half of men and non-pregnant women were initiated on ART within 14 days (men: 39.7.0%, 95% CI 37.7-41.9; women: 39.9%, 95% CI 38.1-41.7). Pregnant women initiated at a faster rate (within 14 days: 87.6%, 86.1-89.0). ART initiation and timeliness varied significantly by district, facility location, and age, with little to no variation by World Health Organization stage, or CD4 count. Men and non-pregnant women newly diagnosed with HIV who are eligible for ART in South Africa show suboptimal timeliness of ART initiation. If treatment initiation performance is not improved, UTT implementation will be challenging among men and non-pregnant women. UTT programming should be tailored to district and location categories to address contextual differences influencing treatment initiation.

Identifiants

pubmed: 30008050
doi: 10.1007/s10461-018-2222-2
pii: 10.1007/s10461-018-2222-2
pmc: PMC6331268
mid: NIHMS988107
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

375-385

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH000391
Pays : United States
Organisme : U.S. President's Emergency Plan for AIDS Relief
ID : 1U2GGH000391

Références

Int J Tuberc Lung Dis. 2015 Jan;19(1):104-10
pubmed: 25519799
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19408
pubmed: 25724504
J Int AIDS Soc. 2015 Oct 26;18:20019
pubmed: 26507824
MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):148-51
pubmed: 23446514
Int J Equity Health. 2012 Jun 12;11:31
pubmed: 22691443
PLoS One. 2010 Nov 02;5(11):e13801
pubmed: 21072191
PLoS One. 2012;7(5):e36792
pubmed: 22606289
J Int AIDS Soc. 2012 Nov 19;15(2):17383
pubmed: 23199799
Public Health Action. 2016 Mar 21;6(1):3-7
pubmed: 27051603
PLoS One. 2015 May 01;10(5):e0125665
pubmed: 25933356
Afr Health Sci. 2014 Dec;14(4):1046-55
pubmed: 25834516
Glob Health Action. 2017;10(1):1305765
pubmed: 28574794
J Health Care Poor Underserved. 2013 Feb;24(1):359-83
pubmed: 23377739
J Antimicrob Chemother. 2013 Jun;68(6):1388-99
pubmed: 23391713
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):314-21
pubmed: 25415291
J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14(6):560-70
pubmed: 26289343
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1281-6
pubmed: 26605861
Afr J AIDS Res. 2016;15(1):67-75
pubmed: 27002359
J Acquir Immune Defic Syndr. 2009 Jul 1;51 Suppl 3:S106-10
pubmed: 19553777
Bull World Health Organ. 2008 Sep;86(9):678-87
pubmed: 18797643
BMC Public Health. 2014 Dec 03;14:1240
pubmed: 25467030
PLoS One. 2017 Jul 10;12(7):e0180843
pubmed: 28700693
Trop Med Int Health. 2007 Jul;12(7):862-72
pubmed: 17596254
Trop Med Int Health. 2012 Dec;17(12):1509-20
pubmed: 22994151
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):436-42
pubmed: 24798765
Int J Tuberc Lung Dis. 2010 Jul;14(7):903-8
pubmed: 20550776
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e41-9
pubmed: 23727981

Auteurs

Anna Larsen (A)

US Centers for Disease Control and Prevention, Pretoria, South Africa. annamlar@gmail.com.

Mireille Cheyip (M)

US Centers for Disease Control and Prevention, Pretoria, South Africa.

Abraham Tesfay (A)

Howard University Global Initiative, Pretoria, South Africa.

Peter Vranken (P)

US Centers for Disease Control and Prevention, Pretoria, South Africa.

Henry Fomundam (H)

Howard University Global Initiative, Pretoria, South Africa.

Anthony Wutoh (A)

Howard University Global Initiative, Pretoria, South Africa.

Getahun Aynalem (G)

US Centers for Disease Control and Prevention, Pretoria, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH